Guggenheim Capital LLC Bristol Myers Squibb CO Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Guggenheim Capital LLC holds 721,278 shares of BMY stock, worth $41.7 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares

721,278

Previous 697,351 3.43%

Holding current value

$41.7 Million

Previous $29 Million 28.89%

% of portfolio

0.27%

Previous 0.21%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$39.66 - $51.75 $948,944 - $1.24 Million	23,927 Added 3.43%	721,278 $37.3 Million
Q2 2024 Aug 14, 2024	BUY	$40.25 - $52.99 $2.06 Million - $2.71 Million	51,188 Added 7.92%	697,351 $29 Million
Q1 2024 May 14, 2024	BUY	$47.98 - $54.4 $5.12 Million - $5.81 Million	106,790 Added 19.8%	646,163 $35 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $1.41 Million - $1.68 Million	29,111 Added 5.71%	539,373 $27.7 Million
Q3 2023 Nov 14, 2023	SELL	$57.89 - $64.73 $1.43 Million - $1.6 Million	-24,647 Reduced 4.61%	510,262 $29.6 Million
Q2 2023 Aug 11, 2023	BUY	$63.71 - $70.74 $3.79 Million - $4.21 Million	59,459 Added 12.51%	534,909 $34.2 Million
Q1 2023 May 10, 2023	SELL	$65.71 - $74.53 $1.88 Million - $2.13 Million	-28,567 Reduced 5.67%	475,450 $33 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $406,702 - $481,593	5,939 Added 1.19%	504,017 $36.3 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $953 - $563,851	-7,338 Reduced 1.45%	498,078 $35.4 Million
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $5.41 Million - $5.96 Million	-74,520 Reduced 12.85%	505,416 $38.9 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $1.92 Million - $2.31 Million	31,269 Added 5.7%	579,936 $42.4 Million
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $3.45 Million - $4.02 Million	64,309 Added 13.28%	548,667 $34.2 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $454,307 - $532,162	7,678 Added 1.61%	484,358 $28.7 Million
Q2 2021 Aug 13, 2021	BUY	$61.91 - $67.42 $5.87 Million - $6.39 Million	94,837 Added 24.84%	476,680 $31.9 Million
Q1 2021 May 13, 2021	BUY	$59.34 - $66.74 $5.62 Million - $6.32 Million	94,715 Added 32.99%	381,843 $24.1 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $484,496 - $549,023	8,391 Added 3.01%	287,128 $17.8 Million
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $1.22 Million - $1.35 Million	-21,210 Reduced 7.07%	278,737 $16.8 Million
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $5.85 Million - $6.84 Million	106,764 Added 55.27%	299,947 $17.6 Million
Q1 2020 Jun 02, 2020	SELL	$46.4 - $67.43 $4.31 Million - $6.26 Million	-92,851 Reduced 32.46%	193,183 $10.8 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $5.41 Million - $7.05 Million	109,854 Added 62.35%	286,034 $18.4 Million
Q3 2019 Nov 14, 2019	BUY	$42.77 - $50.71 $556,223 - $659,483	13,005 Added 7.97%	176,180 $8.93 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $4.04 Million - $4.47 Million	-90,498 Reduced 35.68%	163,175 $7.4 Million
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $3.6 Million - $4.29 Million	-79,790 Reduced 23.93%	253,673 $12.1 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $481,992 - $625,028	9,885 Added 3.05%	333,463 $17.3 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $757,593 - $854,505	13,727 Added 4.43%	323,578 $20.1 Million
Q2 2018 Aug 14, 2018	SELL	$50.53 - $62.98 $31.7 Million - $39.5 Million	-627,880 Reduced 66.96%	309,851 $17.1 Million
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $3.88 Million - $4.47 Million	-64,733 Reduced 6.46%	937,731 $59.3 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $5.9 Million - $6.43 Million	98,469 Added 10.89%	1,002,464 $61.4 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $49.9 Million - $57.6 Million	903,995	903,995 $57.6 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Bristol Myers Squibb CO Transaction History